Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers
Objective Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab treatment in Brazilian patients with multiple sclerosis (MS) followed up for at least 12 months, in two tertiary MS care centers in São Paulo.Method We evaluated the effect of natalizumab treatment on an...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Academia Brasileira de Neurologia (ABNEURO)
2015-09-01
|
| Series: | Arquivos de Neuro-Psiquiatria |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2015000900736&lng=en&tlng=en |
| _version_ | 1818136879087747072 |
|---|---|
| author | Enedina Maria Lobato de Oliveira Renata Faria Simm Gorana Dasic Marília Mamprim de Morais Samira Luiza dos Apostolos Perreira Dagoberto Callegaro |
| author_facet | Enedina Maria Lobato de Oliveira Renata Faria Simm Gorana Dasic Marília Mamprim de Morais Samira Luiza dos Apostolos Perreira Dagoberto Callegaro |
| author_sort | Enedina Maria Lobato de Oliveira |
| collection | DOAJ |
| description | Objective Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab treatment in Brazilian patients with multiple sclerosis (MS) followed up for at least 12 months, in two tertiary MS care centers in São Paulo.Method We evaluated the effect of natalizumab treatment on annualized relapse rate and disability progression in 75 patients with MS treated with natalizumab for at least 12 months. A subgroup analysis was performed to evaluate efficacy of natalizumab treatment in patients with Expanded Disability Status Scale (EDSS) ≤ 3.0 vs patients with EDSS > 3.Results Patients treated for at least one year with natalizumab showed a 91% reduction in aRR, as well and an improvement in neurological disability. The impact of natalizumab treatment was greater in patients with EDSS < 3.0. Overall, natalizumab was safe but one patient developed progressive multifocal leukoencephalopathy.Conclusion Natalizumab as a third line therapy is safe and efficacious, especially in patients with mild neurological disability. |
| first_indexed | 2024-12-11T09:47:25Z |
| format | Article |
| id | doaj.art-e06136b97d094b039fe615a4b6f35b22 |
| institution | Directory Open Access Journal |
| issn | 1678-4227 |
| language | English |
| last_indexed | 2024-12-11T09:47:25Z |
| publishDate | 2015-09-01 |
| publisher | Academia Brasileira de Neurologia (ABNEURO) |
| record_format | Article |
| series | Arquivos de Neuro-Psiquiatria |
| spelling | doaj.art-e06136b97d094b039fe615a4b6f35b222022-12-22T01:12:31ZengAcademia Brasileira de Neurologia (ABNEURO)Arquivos de Neuro-Psiquiatria1678-42272015-09-0173973674010.1590/0004-282X20150098S0004-282X2015000900736Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centersEnedina Maria Lobato de OliveiraRenata Faria SimmGorana DasicMarília Mamprim de MoraisSamira Luiza dos Apostolos PerreiraDagoberto CallegaroObjective Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab treatment in Brazilian patients with multiple sclerosis (MS) followed up for at least 12 months, in two tertiary MS care centers in São Paulo.Method We evaluated the effect of natalizumab treatment on annualized relapse rate and disability progression in 75 patients with MS treated with natalizumab for at least 12 months. A subgroup analysis was performed to evaluate efficacy of natalizumab treatment in patients with Expanded Disability Status Scale (EDSS) ≤ 3.0 vs patients with EDSS > 3.Results Patients treated for at least one year with natalizumab showed a 91% reduction in aRR, as well and an improvement in neurological disability. The impact of natalizumab treatment was greater in patients with EDSS < 3.0. Overall, natalizumab was safe but one patient developed progressive multifocal leukoencephalopathy.Conclusion Natalizumab as a third line therapy is safe and efficacious, especially in patients with mild neurological disability.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2015000900736&lng=en&tlng=ennatalizumabeesclerose múltiplaprogressão da incapacidadetaxa de surto |
| spellingShingle | Enedina Maria Lobato de Oliveira Renata Faria Simm Gorana Dasic Marília Mamprim de Morais Samira Luiza dos Apostolos Perreira Dagoberto Callegaro Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers Arquivos de Neuro-Psiquiatria natalizumabe esclerose múltipla progressão da incapacidade taxa de surto |
| title | Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers |
| title_full | Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers |
| title_fullStr | Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers |
| title_full_unstemmed | Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers |
| title_short | Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers |
| title_sort | natalizumab treatment in multiple sclerosis the experience from two brazilian ms centers |
| topic | natalizumabe esclerose múltipla progressão da incapacidade taxa de surto |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2015000900736&lng=en&tlng=en |
| work_keys_str_mv | AT enedinamarialobatodeoliveira natalizumabtreatmentinmultiplesclerosistheexperiencefromtwobrazilianmscenters AT renatafariasimm natalizumabtreatmentinmultiplesclerosistheexperiencefromtwobrazilianmscenters AT goranadasic natalizumabtreatmentinmultiplesclerosistheexperiencefromtwobrazilianmscenters AT mariliamamprimdemorais natalizumabtreatmentinmultiplesclerosistheexperiencefromtwobrazilianmscenters AT samiraluizadosapostolosperreira natalizumabtreatmentinmultiplesclerosistheexperiencefromtwobrazilianmscenters AT dagobertocallegaro natalizumabtreatmentinmultiplesclerosistheexperiencefromtwobrazilianmscenters |